You did the sensible thing. The estrogen went on, the night sweats settled, the sleep came back. And still something has not returned. The drive is flat. The word you want does not arrive when you reach for it. You feel, in a way that is hard to say out loud, less like yourself than you used to be.

For a proportion of women, the missing piece is the hormone almost nobody thinks to replace.

Testosterone is treated in public conversation as a men's hormone. It is not. Women produce it too, in the ovaries and in the adrenal glands, and they depend on it. What follows is the honest position: where the evidence is solid, where it is only promising, and where the marketing has run considerably ahead of the science.

The Overlooked Half

Estrogen gets replaced. Testosterone usually does not, even when it is the hormone you are missing.

The Hormone That Does Not Stop at Menopause

Here is a fact that surprises most women, and a good number of doctors. At menopause the ovary stops producing estradiol, the main form of estrogen, because the follicles that made it are gone. But the ovary continues to secrete testosterone. Production does not switch off at the final period. It declines gradually with age instead, beginning years earlier, which is why the fall is so easy to miss.

That gradual decline is part of why testosterone deficiency in women is rarely diagnosed. There is no dramatic event to point to. There is only a slow subtraction: desire, drive, confidence, mental sharpness, the sense of being fully present in your own life.

It is also why a single blood test does not settle the question. Testosterone levels in women are low by design, sit close to the lower limit of what many laboratory assays can reliably measure, and vary through the day. The diagnosis is clinical. The blood test is there to guide the dose and to keep you inside a safe range, not to hand you a verdict.

What the Evidence Actually Supports

This is where we are deliberately conservative, because you deserve the real answer rather than the flattering one.

The European Society of Endocrinology clinical practice guideline on menopause and the perimenopause, published in 2025, is explicit. Hypoactive sexual desire disorder in postmenopausal women is the only evidence-based indication for testosterone therapy in women. Hypoactive sexual desire disorder, usually shortened to HSDD, means persistently low sexual desire that causes you genuine personal distress. The distress matters. Low desire that does not trouble you is not a disease.

The same guideline sets three conditions on how it should be given, and each one is doing real work:

For the practical detail of dosing and monitoring, that guideline refers clinicians to the Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published by Davis and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2019. It remains the reference document internationally.

Replacement to a healthy young woman's range. Not a dose above it. That single distinction separates careful endocrinology from the clinics that make women hairy and hoarse.

What the Newest Data Suggest, and What They Do Not Prove

The interesting question, and the one women actually ask, is whether testosterone does anything for mood and for the mental fog that so many describe during and after the transition.

A study published in Archives of Women's Mental Health in 2025 looked at exactly this. Researchers at a specialist menopause clinic in the United Kingdom followed 510 women who were already taking HRT and who still had persistent low libido together with cognitive and low mood symptoms. Each was treated with transdermal testosterone cream or gel for four months, and symptoms were scored before and after using a modified version of the Greene Climacteric Scale, a standard menopause symptom questionnaire.

All nine mood and cognitive symptoms measured improved significantly over the study period. Mood improved more than thinking did.

52% libido  |  47% mood  |  39% cognition Proportion of 510 women reporting improvement after four months of transdermal testosterone, on top of existing HRT. Mean symptom scores fell by 33, 34 and 22 percent respectively.

Now the limitation, stated before the sales pitch and not after it. This was a retrospective cohort study with no control group and no placebo arm. The authors themselves describe it as a pilot and call for randomized trials. Symptom questionnaires improve substantially on placebo alone in menopause research, so some part of that improvement is not the drug. This study cannot tell us how much.

What it does tell us is that the effect is worth taking seriously, that mood may respond more readily than cognition, and that the benefit appears to extend beyond desire alone. That is a reasonable basis for a carefully monitored trial of treatment in the right woman. It is not a basis for prescribing testosterone to every woman with a tiring week behind her.

What Testosterone Is Not For

Being clear about this protects you.

It is not a bone treatment. Adding an androgen to estrogen therapy does not appear to increase bone density more than estrogen on its own, and androgens carry virilizing effects, meaning masculinizing changes such as unwanted hair growth, acne, and deepening of the voice. If bone is your concern, the answer is a bone strategy, not testosterone.

It is not a general tonic. There is no good evidence for prescribing it to women with no symptoms in the hope of a longevity benefit.

It is not a substitute for estrogen. Testosterone is considered in women who are already on appropriate hormone therapy and still have a specific unresolved problem. It is an addition to a well-built regimen, not a shortcut around one.

What Careful Prescribing Looks Like

This is where the difference between a specialist and a prescription pad becomes visible, and it is the part we take seriously.

Who Should Not Take It

Testosterone is not appropriate in pregnancy or breastfeeding, in women with an active hormone-sensitive cancer without oncology input, or in women with untreated significant liver disease. Women with a history of breast cancer need a decision made together with their oncologist. If you have unexplained bleeding after menopause, that must be investigated before any hormone is started, whatever the hormone.

The Honest Summary

Strong evidence for desire. Encouraging but unproven for mood and clarity. Wrong tool for bone. Right dose, right route, or not at all.

How We Decide With You

A consultation about testosterone begins with the question of whether testosterone is the answer at all. We look at your full hormonal picture, at your existing regimen, at sleep, thyroid, mood, medication, and at the local symptoms that so often go unmentioned and that quietly destroy desire on their own.

If testosterone is the right addition, it is prescribed transdermally, at replacement dose, with blood monitoring, and with a defined point at which we judge whether it worked. If it is not the right addition, we say so, and we treat the thing that actually is the problem.

If you are already on HRT and still do not feel like yourself, that is worth a proper conversation.

Message us on WhatsApp

Where These Figures Come From

Related Reading